7zjf

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (14:17, 6 November 2024) (edit) (undo)
 
(One intermediate revision not shown.)
Line 4: Line 4:
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[7zjf]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7ZJF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7ZJF FirstGlance]. <br>
<table><tr><td colspan='2'>[[7zjf]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7ZJF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7ZJF FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7zjf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7zjf OCA], [https://pdbe.org/7zjf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7zjf RCSB], [https://www.ebi.ac.uk/pdbsum/7zjf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7zjf ProSAT]</span></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.3&#8491;</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7zjf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7zjf OCA], [https://pdbe.org/7zjf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7zjf RCSB], [https://www.ebi.ac.uk/pdbsum/7zjf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7zjf ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
Line 12: Line 13:
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
-
OBJECTIVE: To preclinically characterize a mutant form of growth and differentiation factor 5 (GDF5, R399E) with reduced osteogenic properties, as a potential disease-modifying osteoarthritis (OA) drug. METHODS: Cartilage, synovium and meniscus from patients with OA were used to evaluate anabolic and anti-inflammatory properties of R399E. In the rabbit joint instability model, 65 rabbits underwent transection of the anterior cruciate ligament plus partial meniscectomy. Three intra-articular (IA) R399E doses were administered bi-weekly 6 times and static incapacitance was determined to assess joint pain. OA was evaluated 13 weeks after surgery. In sheep, medial meniscus transection was performed to induce OA, dynamic weight bearing was measured in-life, and OA was assessed after 13 weeks. RESULTS: Intermittent exposure to R399E (1 week per month) was sufficient to induce cell proliferation and release of anabolic markers in chondrocyte 3D cultures. R399E also inhibited the release of interleukin (IL)-1beta, IL-6 and prostaglandin E2 (PGE2) from cartilage with synovium, meniscal cell and synoviocyte cultures. In rabbits, mean difference (95% confidence interval (CI)) in weight bearing for R399E vs. vehicle was -5.8 (-9.54, -2.15), -7.2 (-10.93, -3.54) and -7.7 (-11.49, -3.84) for 0.6, 6 and 60 mug doses 6 hours after first IA injection, and was statistically significant through the entire study for all doses. Cartilage surface structure improved with the 6 mug dose. Structural and symptomatic improvement with the same dose was confirmed in the sheep model of OA. CONCLUSION: R399E influences several pathological processes contributing to OA, highlighting its potential as a disease-modifying therapy.
+
OBJECTIVE: To preclinically characterize a mutant form of growth and differentiation factor 5, R399E, with reduced osteogenic properties as a potential disease-modifying osteoarthritis (OA) drug. METHODS: Cartilage, synovium, and meniscus samples from patients with OA were used to evaluate anabolic and antiinflammatory properties of R399E. In the rabbit joint instability model, 65 rabbits underwent transection of the anterior cruciate ligament plus partial meniscectomy. Three intraarticular (IA) R399E doses were administered biweekly 6 times, and static incapacitance was determined to assess joint pain. OA was evaluated 13 weeks after surgery. In sheep, medial meniscus transection was performed to induce OA, dynamic weight bearing was measured in-life, and OA was assessed after 13 weeks. RESULTS: Intermittent exposure to R399E (1 week per month) was sufficient to induce cell proliferation and release of anabolic markers in 3-dimensional chondrocyte cultures. R399E also inhibited the release of interleukin-1beta (IL-1beta), IL-6, and prostaglandin E(2) from cartilage with synovium, meniscal cell, and synoviocyte cultures. In rabbits, the mean difference (95% confidence interval [95% CI]) in weight bearing for R399E compared to vehicle was -5.8 (95% confidence interval [95% CI] -9.54, -2.15), -7.2 (95% CI -10.93, -3.54), and -7.7 (95% CI -11.49, -3.84) for the 0.6, 6, and 60 mug doses, respectively, 6 hours after the first IA injection, and was statistically significant through the entire study for all doses. Cartilage surface structure improved with the 6-mug dose. Structural and symptomatic improvement with the same dose was confirmed in the sheep model of OA. CONCLUSION: R399E influences several pathologic processes contributing to OA, highlighting its potential as a disease-modifying therapy.
-
R399E, a mutated form of Growth and Differentiation Factor 5, for disease modification of osteoarthritis.,Gigout A, Werkmann D, Menges S, Brenneis C, Henson F, Cowan KJ, Musil D, Thudium CS, Guhring H, Michaelis M, Kleinschmidt-Doerr K Arthritis Rheumatol. 2022 Sep 2. doi: 10.1002/art.42343. PMID:36054172<ref>PMID:36054172</ref>
+
R399E, A Mutated Form of Growth and Differentiation Factor 5, for Disease Modification of Osteoarthritis.,Gigout A, Werkmann D, Menges S, Brenneis C, Henson F, Cowan KJ, Musil D, Thudium CS, Guhring H, Michaelis M, Kleinschmidt-Doerr K Arthritis Rheumatol. 2023 Mar;75(3):375-386. doi: 10.1002/art.42343. Epub 2022 , Dec 15. PMID:36054172<ref>PMID:36054172</ref>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
</div>
<div class="pdbe-citations 7zjf" style="background-color:#fffaf0;"></div>
<div class="pdbe-citations 7zjf" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Growth differentiation factor 3D STRUCTURES|Growth differentiation factor 3D STRUCTURES]]
== References ==
== References ==
<references/>
<references/>

Current revision

R399E, a mutated form of GDF5, for disease modification of osteoarthritis

PDB ID 7zjf

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools